Crescent Biopharma (FRA:C68) Total Receivables: €0.00 Mil (As of Mar. 2026)


FRA:C68 Crescent Biopharma Inc FRA:C68
10 GF Score
Price €14.60
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Total Receivables?

Crescent Biopharma FRA:C68 10 Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Crescent Biopharma's Total Receivables for the quarter that ended in Mar. 2026 was €0.00 Mil.

Crescent Biopharma Total Receivables Related Terms

Crescent Biopharma Total Receivables Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Total Receivables Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Total Receivables
0.00 15.37

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial 0.00 0.00 0.00 15.37 0.00
FRA:C68
10GF Score
Crescent Biopharma Inc FRA:C68
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.00 Mil mean?
Crescent Biopharma (FRA:C68) has a Total Receivables of €0.00 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's Total Receivables too high?
Crescent Biopharma's current Total Receivables is €0.00 Mil. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Total Receivables compare to KYTX and ZURA?
Crescent Biopharma's Total Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Total Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Total Receivables of €0.00 Mil. The current Total Receivables is €0.00 Mil. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Total Receivables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for FRA:C68

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price